A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers.

Eduardo Gonzalez-OchoaMichael MilosevicBradley CorrJames L AbbruzzeseEugenia GirdaRachel W MillerJennifer CrokeHelen MackayYeh Chen LeeValerie BoweringJanelle RamsahaiLisa WangApril D'SouzaCharles A KunosAmit M OzaPamela Denisse Soberanis-Piña

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2023)

The recommended phase II dose could not be determined due to clinical toxicity and early trial closure. Preliminary efficacy appears promising, yet selecting the adequate dose/schedule in combination chemoradiation warrants further investigation to limit overlapping toxicities.

Keyphrases

phase ii
clinical trial
open label
rectal cancer
phase iii
locally advanced
double blind
placebo controlled
study protocol
oxidative stress
radiation therapy